Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
Company research
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company headquartered in Florham Park, New Jersey, focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's lead asset is vonoprazan, a first-in-class oral potassium-competitive acid blocker (P-CAB) and the only PCAB approved for marketing in the United States, commercialized under the VOQUEZNA® brand — including VOQUEZNA® DUAL PAK® and VOQUEZNA® TRIPLE PAK® — for the treatment of erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori infection. Phathom holds exclusive commercial rights to vonoprazan across the United States, Europe, and Canada, and continues to explore its potential in additional indications such as non-erosive GERD and eosinophilic esophagitis. Founded in 2018 and having completed its IPO in October 2019, the company has demonstrated strong revenue momentum, reporting a 104% year-over-year increase in Q1 2026 net revenues of $58.3 million, with a current market capitalization of approximately $875 million.
Research reports
Consolidates the views of three Wall Street analysts with a current consensus rating of Strong Buy on PHAT and a stated price target of 23, highlighting strong VOQUEZNA prescription growth, expanded GERD market opportunity, and a commercialization strategy focused on GI specialists while noting ongoing net losses and execution risks around product development, reimbursement, and sustained revenue growth.
ValueInvesting.io · June 15, 2026PHAT Intrinsic Value and DCF Valuation (Growth Exit 5Y)Applies a discounted cash flow (Growth Exit 5Y) framework to PHAT and concludes that the intrinsic value is significantly negative relative to the current market price, implying PHAT is heavily overvalued, and presents multiple DCF scenario ranges and upside calculations that support a sell stance while cautioning that model constraints may affect precision.
Zacks Investment Research (Advisor Tools) · January 9, 2026Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) – Zacks Rank & Style Score Snapshot (Report Date January 09, 2026)Provides a quantitative equity research snapshot with a Zacks Rank of 3‑Hold, detailing consensus EPS revisions, projected sales growth of about 80% year‑over‑year, deeply negative net margin, and industry‑relative valuation metrics, and explains the Zacks Rank and Style Score methodology while characterizing PHAT as a clinical‑stage GI biopharmaceutical with vonoprazan‑based products.
Zacks Investment Research (Advisor Tools) · January 6, 2026Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) – Zacks Rank & Style Score Snapshot (Report Date January 06, 2026)Presents an earlier but very similar Zacks equity research snapshot on PHAT with a Zacks Rank of 3‑Hold, summarizing estimate revisions, earnings surprise history, high projected EPS and sales growth alongside very negative profitability metrics, and positioning PHAT within the Medical – Biomedical and Genetics industry while reiterating the methodology behind the rank and style scores rather than a directional buy/sell call.